UPDATE: TOPROL-XL and generic metoprolol succinate*—all 4 strengths widely available
We are pleased to provide you with follow-up information to our recent letter regarding the availability of TOPROL-XL
and its generic equivalent, metoprolol succinate extended-release tablets.
Over the last several weeks, a significant quantity of TOPROL-XL and generic metoprolol succinate has been delivered to
the US market. Because we are shipping TOPROL-XL and its generic metoprolol succinate to our wholesaler and distribution
partners in quantities that exceed historical levels, we expect no more shortages at retail pharmacies across the country.
If you have found it necessary to switch any of your hypertensive patients to the immediate-release formulation, metoprolol
tartrate, please be assured that the once-daily extended-release is widely available, both as branded TOPROL-XL and as
TOPROL-XL and metoprolol succinate are available in 4 dosages to suit individual patient needs: 25 mg, 50 mg, 100 mg, and
TOPROL-XL, a beta1–selective (cardioselective) adrenoceptor blocking agent for oral administration is available as
extended-release tablets. TOPROL-XL is a once-a-day beta-blocker indicated for the treatment of hypertension, alone
or in combination with other antihypertensive agents.
TOPROL-XL is contraindicated in severe bradycardia, heart block of greater than first degree, cardiogenic shock, decompensated
cardiac failure, sick sinus syndrome (unless a permanent pacemaker is in place), and in patients who are hypersensitive to any
Following abrupt cessation of therapy with certain beta-blocking agents, exacerbations of angina pectoris and, in some
cases, myocardial infarction have occurred. When discontinuing chronical y administered TOPROL-XL, particularly in
patients with ischemic heart disease, the dosage should be gradually reduced over a period of 1–2 weeks and the
patient should be carefully monitored. If angina markedly worsens or acute coronary insufficiency develops, TOPROL-XL
administration should be reinstated promptly, at least temporarily, and other measures appropriate for the management
of unstable angina should be taken. Patients should be warned against interruption or discontinuation of therapy without
the physician’s advice. Because coronary artery disease is common and may be unrecognized, it may be prudent not to
discontinue TOPROL-XL therapy abruptly even in patients treated only for hypertension.
In clinical trials of patients with hypertension and angina pectoris the most common adverse events reported with immediate-
release metoprolol tartrate are tiredness (10%), dizziness (10%), depression (5%), diarrhea (5%), pruritus or rash (5%), shortness
of breath (3%), and bradycardia (3%).
Please see accompanying full Prescribing Information, including boxed WARNING regarding abrupt cessation of therapy.
We want to thank you again for your patience and understanding during this process.
If you have any questions, please call the AstraZeneca Information Center at 1-800-236-9933, between the hours of
8:00 am and 6:00 Pm EST, Monday through Friday.
*Manufactured for Par Pharmaceutical Companies, Inc. by AstraZeneca AB, Södertälje, Sweden. TOPROL-XL is a registered trademark of the AstraZeneca group of companies.
2009 AstraZeneca LP. All rights reserved. 281671 5/09
Attenuation of SSRI-induced increases in extracellular brain 5-HT by benzodiazepines Chapter 8 Attenuation of SSRI-induced increases in extracellular brain 5-HT by benzodiazepines. Abstract Enhanced serotonergic neurotransmission is generally thought to be the neurochemical basisof the antidepressant effects of Selective Serotonin Reuptake Inhibitors (SSRIs). The anxiolytic benzodiaz
Octubre es el mes mundial de lucha contra el cáncer de mama, una enfermedad de la que enferman 1.800 uruguayas cada año, -una de cada ocho- enferman de cáncer de mama, y 650 fallecen. Control del consumo de tabaco y alcohol. Control de agentes infecciosos incluyendo la Aumento de la acti vidad fí sicaControl del peso corporalEvitar la terapia de reemplazamiento hormo-